BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim KH, Choi KU, Kim A, Lee SJ, Lee JH, Suh DS, Kwon BS, Hwang C. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. J Ovarian Res 2019;12:56. [PMID: 31208449 DOI: 10.1186/s13048-019-0526-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu C, Lin J, Weng Y, Zeng DN, Xu J, Luo S, Xu L, Liu M, Hua Q, Liu CQ, Li JQ, Liao J, Sun C, Zhou J, Chen MS, Liu C, Guo Z, Zhuang SM, Huang JH, Zheng L. Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. J Clin Invest 2020;130:4679-93. [PMID: 32497024 DOI: 10.1172/JCI135048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
2 Blanc-Durand F, Genestie C, Galende EY, Gouy S, Morice P, Pautier P, Maulard A, Mesnage S, Le Formal A, Brizais C, Richardson M, Leary A. Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape. Gynecol Oncol 2021;160:279-84. [PMID: 33162175 DOI: 10.1016/j.ygyno.2020.09.045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Kim KH, Choi KU, Kim A, Lee SJ, Lee JH, Suh DS, Kwon BS, Hwang C. Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. J Ovarian Res 2019;12:68. [PMID: 31337420 DOI: 10.1186/s13048-019-0540-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Zhang C, Yang Q. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis. Front Oncol 2020;10:572203. [PMID: 33634012 DOI: 10.3389/fonc.2020.572203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wu Z, Man S, Sun R, Li Z, Wu Y, Zuo D. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer. International Immunopharmacology 2020;85:106613. [DOI: 10.1016/j.intimp.2020.106613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
6 Lee SW, Lee HY, Kang SW, Kim MJ, Lee YJ, Sung CO, Kim YM. Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian Cancer. Int J Mol Sci 2021;22:9638. [PMID: 34502561 DOI: 10.3390/ijms22179638] [Reference Citation Analysis]
7 Li M, Li H, Zhou C, Li X, Gong J, Chen C, Zhang Y. Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of hepatocellular carcinoma (HCC). Medicine (Baltimore) 2021;100:e27332. [PMID: 34596136 DOI: 10.1097/MD.0000000000027332] [Reference Citation Analysis]
8 Eymerit-Morin C, Ilenko A, Gaillard T, Varinot J, Compérat E, Bendifallah S, Darai E. PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases. Eur J Histochem 2021;65. [PMID: 33728864 DOI: 10.4081/ejh.2021.3185] [Reference Citation Analysis]
9 Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan DM, Poggi A, Bruno A, Mortara L. The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. Int J Mol Sci 2020;21:E3125. [PMID: 32354198 DOI: 10.3390/ijms21093125] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
10 Liu S, Wu M, Wang F. Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer. J Cancer 2021;12:3976-96. [PMID: 34093804 DOI: 10.7150/jca.47695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Pivetta E, Spessotto P. Multispectral imaging technology: Visualize, analyze, phenotyping, and quantify immune cells in situ. Int J Biol Markers 2020;35:26-30. [PMID: 32079464 DOI: 10.1177/1724600819896810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
12 Melaiu O, Lucarini V, Giovannoni R, Fruci D, Gemignani F. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Semin Cancer Biol 2020:S1044-579X(20)30156-5. [PMID: 32659257 DOI: 10.1016/j.semcancer.2020.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
13 Vimalathas G, Kristensen BW. Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas. Neuropathol Appl Neurobiol 2021. [PMID: 34533233 DOI: 10.1111/nan.12767] [Reference Citation Analysis]
14 Patel JJ, Levy DA, Nguyen SA, Knochelmann HM, Day TA. Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis. Head Neck 2020;42:774-86. [PMID: 31762164 DOI: 10.1002/hed.26036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
15 Choi KU, Kim A, Kim JY, Kim KH, Hwang C, Lee SJ, Park WY, Jung S, Choi HJ, Kim K. Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma. J Ovarian Res 2020;13:65. [PMID: 32513298 DOI: 10.1186/s13048-020-00667-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
16 Li H, Wang J. [Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:131-40. [PMID: 33508897 DOI: 10.3779/j.issn.1009-3419.2021.102.06] [Reference Citation Analysis]
17 Chen H, Molberg K, Strickland AL, Castrillon DH, Carrick K, Jiang Q, Niu S, Rivera-Colon G, Gwin K, Hinson S, Lea J, Miller DS, Zheng W, Lucas E. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma. Am J Surg Pathol 2020;44:1050-60. [PMID: 32384321 DOI: 10.1097/PAS.0000000000001503] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Bekos C, Pils D, Dekan S, Hofstetter G, Horak P, Reinthaller A, Polterauer S, Schwameis R, Aust S. PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome. Sci Rep 2021;11:6400. [PMID: 33737722 DOI: 10.1038/s41598-021-85966-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]